Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities.
Key facts
- Who runs it
- Hualien Tzu Chi General Hospital
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 610 people, planned
- Started
- 2 Apr 2024
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 3 groups
- Treatments tested
- Takepron
- Zoloft 50Mg Tablet
- Imipramine Pill
- Record updated
- 8 September 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Age between 18 and 75 years, with clear consciousness and willingness to sign the informed consent form
- Subjects with chronic esophageal symptoms related to disorders of the brain-gut axis communication (such as heartburn, acid reflux, sensation of a foreign body in the throat, difficulty swallowing, and chest pain or discomfort)
Who cannot take part
- Use of or currently taking antidepressants, selective serotonin reuptake inhibitors, or other psychotropic medications within the past three months
- Esophageal strictures, or history of surgery on the esophagus, gastrointestinal tract, or throat
- Structural esophageal diseases (such as diverticula, esophageal rings, etc.), infectious esophagitis, erosive esophagitis, eosinophilic esophagitis
- Non-erosive gastroesophageal reflux disease or significant esophageal motility disorders
- History of or current diagnosis of malignancies in the esophagus, gastrointestinal tract, or other organs
- Significant endocrine or rheumatic immune diseases that may affect gastrointestinal motility
- Individuals with mental illness or those who are unable to cooperate
- Known allergy to tricyclic antidepressants
- Known allergy to selective serotonin reuptake inhibitors
- Known allergy to any component of proton pump inhibitors
- Continuous use of medications that may affect esophageal motility within the past month (such as anticholinergics, opioid-like agents, nitrates, calcium channel blockers, etc.)
- Pregnant or breastfeeding women
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Gut-brain disorders or GERD without erosive esophagitis
This trial is currently available in Taiwan.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Gastroesophageal reflux disease (GERD) poses a challenging medical condition to manage, with up to 40% of patients showing refractory to standard medical intervention, which usually begins with a proton pump inhibitor (PPI). Among these cases, esophageal disorders of gut-brain interaction (DGBI), such as reflux hypersensitivity and functional heartburn, or GERD patients with concurrent occurrences of these conditions, constitute more than 90% of the patients who did not respond to twice-daily PPI treatment. Esophageal visceral hypersensitivity and hypervigilance are the two pathways that drive esophageal DGBI and symptoms. The Rome IV esophageal disorders, encompassing functional chest pain, functional heartburn, globus, functional dysphagia, and reflux hypersensitivity, are defined by present with symptoms originating from the esophagus without detectable evidence of structural, inflammatory, or motor disorders. Diagnosing esophageal DGBI necessitates testing involving endoscopy, pH-impedance monitoring, and high-resolution manometry. Neuromodulators form the basis of the pharmacological strategy for managing various esophageal DGBI and symptoms, modulating both peripheral and central hyperalgesia. Increasing evidence supports the use of brain-gut behavioral therapies, such as gut-directed hypnotherapy and cognitive behavior therapy, as effective treatments for a variety of DGBIs. However, the efficacy of neuromodulators in treating esophageal DGBI and related symptoms remains largely unexplored. The primary objective of this study is to examine the efficacy of neuromodulators in managing esophageal DGBI. Additionally, investigators will explore various classes of neuromodulators and subtypes of esophageal DGBI to ascertain whether there are differing levels of effectiveness across these conditions. The findings from this study will contribute to a better understanding of the pathophysiology of esophageal DGBI and GERD with refractory symptoms. These clinical insights may then offer valuable guidance for future therapeutic approaches in DGBI patients who experience esophageal symptoms and do not respond to PPI treatment.
The 3 groups in the trial
- tricyclic antidepressant, TCATreatment being tested
The main component of tricyclic antidepressants (TCA) is imipramine HCL. Imipramine has various pharmacological effects, including alpha-adrenergic antagonism, antihistamine activity, anticholinergic effects, and blockade of 5-HT3 receptors. The exact mechanism of imipramine's antidepressant action is unknown, but it may primarily involve the inhibition of the reuptake of norepinephrine (NA) and serotonin (5-HT), without including a stimulatory effect on the central nervous system. Indications/Expected Uses: Depression and nocturia.
Treatment: Imipramine Pill
- selective serotonin reuptake inhibitor, SSRITreatment being tested
The mechanism of action of the selective serotonin reuptake inhibitor (SSRI) sertraline is believed to be related to the inhibition of serotonin (5-HT) reuptake in the central nervous system. Clinical studies have confirmed that when humans receive appropriate doses of sertraline, it can inhibit the reuptake of serotonin into platelets in the body. Indications/Expected Uses: Depression, obsessive-compulsive disorder (OCD), panic disorder, post-traumatic stress disorder (PTSD), social anxiety disorder, and premenstrual dysphoric disorder (PMDD).
Treatment: Zoloft 50Mg Tablet
- proton-pump inhibitor, PPITreatment being tested
Proton-pump inhibitors (PPIs) inhibit gastric acid secretion by specifically targeting the (H+, K+)-ATPase enzyme system on the surface of gastric parietal cells. This enzyme system can be considered an acid (proton) pump within the parietal cells, blocking the final step of gastric acid production. As a result, they are classified as gastric acid pump inhibitors, effectively reducing both basal and stimulated gastric acid secretion, independent of stimulation. Lansoprazole does not possess anticholinergic or histamine H2-receptor antagonist activity. Indications/Expected Uses: Treatment of gastric ulcers, duodenal ulcers, gastroesophageal reflux disease (GERD) with erosive esophagitis, and management of symptoms related to GERD. It is also used in Zollinger-Ellison syndrome, in combination with antibiotic treatment for Helicobacter pylori-related peptic ulcers, and for the treatment of gastric ulcers induced by NSAIDs.
Treatment: Takepron
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Esophageal Visceral Hypersensitivity and Hypervigilance in Disorders of Gut-brain Interaction: the Roles of Neuromodulators
- Criteria questions
- Built from NCT06778824, who can take part
- Record updated
- 8 September 2026